Proactive Investors
26 May 2026, 11:45 UTC · 17w ago
Verdict
Headline takes no side. We score ONT +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
RBC Capital Markets and Citi have reiterated buy-equivalent ratings for Oxford Nanopore Technologies following its annual customer conference.
More positive than 92% of claims this week
Oxford Nanopore is launching a new PromethION Plus flow cell that increases data output by 20% and lowers genome sequencing costs to roughly $400.
So whatImproved cost-competitiveness and efficiency in a core product line enhance the company's market share potential.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
The company has developed a first amino acid caller for protein sequencing, successfully identifying 22 E. coli proteins.
More positive than 77% of claims this week
Oxford Nanopore is expanding its biopharma partnerships with quality control workflows for mRNA vaccines, engaging partners like Moderna, Pfizer, and BioNTech.
More positive than 77% of claims this week
The company has appointed new Chief Medical, Information, and People officers to strengthen operational capability and clinical applications.
So whatManagement upgrades suggest a shift toward operational scaling and clinical execution, though the immediate market impact is lower than product news.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Received positive reviews and reiterated buy ratings from RBC Capital Markets and Citi following a successful customer conference.
More positive than 57% of ticker scores this week
A portfolio company is partnering to scale a bio-based alternative to ceramic tiles.
More positive than 47% of ticker scores this week
Mentioned as a partner working with Oxford Nanopore's technology.
More positive than 47% of ticker scores this week
Mentioned as a partner working with Oxford Nanopore's technology.
More positive than 47% of ticker scores this week
Mentioned as a partner working with Oxford Nanopore's technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
7h ago
More positive than 35% of relationship scores this week
[mutual] Pfizer is listed as a partner working with Oxford Nanopore's technology.
More positive than 35% of relationship scores this week
[mutual] BioNTech is listed as a partner working with Oxford Nanopore's technology.
More positive than 35% of relationship scores this week
[mutual] Moderna is listed as a partner working with Oxford Nanopore's technology.
More positive than 35% of relationship scores this week
[mutual] Regeneron is listed as a partner working with Oxford Nanopore's technology.
+2.3%
Price agrees with the score
$17.02 vs $16.63 close before publication (May 22) · not market-adjusted
ONT chart →
